4 unknown. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Unknown 4 |
| Phase 2 | 1 | Unknown 1 |
Follow Diffuse Large B-cell Lymphoma: new trials by email Literature Review of Diffuse Large B-cell Lymphoma trials Research Report on Diffuse Large B-cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma CD19-7×19 CAR-T plus PD1 monoclonal antibody - Diffuse Large B-cell Lymphoma | Phase 1 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 24 | 2020-06-18 | 2023-02-06 |
| CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma CTA101 - Diffuse Large B-cell Lymphoma | Phase 1 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 9 | 2019-12-01 | 2019-10-31 |
| Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma. Human CD19 targeted T Cells Injection - CD19-positive, Diffuse Large B-cell Lymphoma | Phase 1 | Unknown | Hrain Biotechnology Co., Ltd. | 18 | 2018-11-13 | 2021-08-31 |
| Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma Cyclophosphamide, Cytarabine, Doxorubicin Hydrochloride - Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma | Phase 1 / Phase 2 | Unknown | Northwestern University | 38 | 2015-10-28 | 2022-02-21 |
Lymphoma, Large B-Cell, Diffuse (4) · Burkitt Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Follicular (1) · Plasmablastic Lymphoma (1)
Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Lymphoma (4) · Lymphoma, Non-Hodgkin (4) · Lymphoproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Lymphoma, B-Cell (3) · DNA Virus Infections (1) · Epstein-Barr Virus Infections (1) · Herpesviridae Infections (1) · Infections (1) · Tumor Virus Infections (1)
Cyclophosphamide (1) · Cytarabine (1) · Doxorubicin (1) · Etoposide (1) · Hydrocortisone (1) · Methotrexate (1) · Prednisone (1) · Rituximab (1) · Vincristine (1) · deltacortene (1) · ixazomib (1) · merphos (1) · prednylidene (1)
Hrain Biotechnology Co., Ltd. (1) · Northwestern University (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · The First Affiliated Hospital with Nanjing Medical University (1)
China (3) · United States (1)
Barbara Pro, MD (1) · Wenbin Qian, MD, PhD (1)
PMID 34515338, PMID 36536403, PMID 38237077
P30CA060553 (1)